The EU medicines regulator has supported the emergency use of Merck’s pill for the treatment of clinically vulnerable Covid-19 patients as cases increase across the continent.
Friday, the European Medicines Agency (EMA) “issued advice”Supporting the emergency use of the drug developed by Merck in collaboration with Ridgeback Biotherapeutics, although it has not yet been cleared by national authorities.
In a statement, the drug regulator said the drug called Lagevrio – also known as molnupiravir or MK 4482 – “can be used to treat adults with Covid-19 who do not need supplemental oxygen and who are at increased risk of developing severe Covid-19.“
He said treatment should be given as soon as possible after being diagnosed with Covid-19 and within five days of onset of symptoms. The drug should be taken twice a day for a period of five days.
The EMA has listed the potential side effects of the capsules, including mild to moderate diarrhea, nausea, dizziness, and headache. The treatment is not recommended for pregnant women.
The watchdog announced earlier on Friday that it had started reviewing Pfizer’s drug Paxlovid for Covid-19 with the same goal “support national authoritiesWhich could decide on its early use before the marketing authorization given the increase in cases and deaths in Europe.
Austria on Friday announced it would enter a new national lockdown from Monday and make vaccination mandatory, while German health officials claimed the country had become “”a big epidemic. “
Pfizer and Merck have both sought approval for their coronavirus drugs from the U.S. Food and Drug Administration, but it’s unclear when that might be granted.
Do you think your friends would be interested? Share this story!